%PDF-1.7 1 0 obj << /Type /Catalog /Outlines 2 0 R /Pages 3 0 R >> endobj 2 0 obj << /Type /Outlines /Count 0 >> endobj 3 0 obj << /Type /Pages /Kids [6 0 R 13 0 R ] /Count 2 /Resources << /ProcSet 4 0 R /Font << /F1 8 0 R /F2 9 0 R /F3 10 0 R >> /ExtGState << /GS1 11 0 R /GS2 12 0 R >> >> /MediaBox [0.000 0.000 595.280 841.890] >> endobj 4 0 obj [/PDF /Text ] endobj 5 0 obj << /Producer (dompdf 3.1.0 + CPDF) /CreationDate (D:20260525130501+00'00') /ModDate (D:20260525130501+00'00') >> endobj 6 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Contents 7 0 R >> endobj 7 0 obj << /Length 4362 >> stream 0.000 0.000 0.000 rg BT 35.000 797.842 Td /F1 19.5 Tf [(Treadwell Therapeutics Announces Presentations at the 2022)] TJ ET BT 35.000 774.033 Td /F1 19.5 Tf [(San Antonio Breast Cancer Symposium Featuring a Clinical)] TJ ET BT 35.000 750.223 Td /F1 19.5 Tf [(Trial Update on the CFI-402257 and CFI-400945 programs)] TJ ET BT 35.000 710.207 Td /F3 14.0 Tf [(Description)] TJ ET BT 35.000 669.017 Td /F1 12.0 Tf [(NEW YORK, Nov. 21, 2022 /PRNewswire/ ?? Treadwell Therapeutics, a clinical-stage biotechnology)] TJ ET BT 35.000 654.365 Td /F1 12.0 Tf [(company developing novel medicines for highly aggressive cancers, today announced that four)] TJ ET BT 35.000 639.713 Td /F1 12.0 Tf [(abstracts highlighting CFI-402257 and CFI-400945, the Company??s potent and selective inhibitors of)] TJ ET BT 35.000 625.061 Td /F1 12.0 Tf [(TTK and PLK4, respectively, have been accepted for presentation at the 2022 San Antonio Breast)] TJ ET BT 35.000 610.409 Td /F1 12.0 Tf [(Cancer Symposium \(SABCS\) being held from December 6-10, 2022 at the Henry B. Gonzalez)] TJ ET BT 35.000 595.757 Td /F1 12.0 Tf [(Convention Center in San Antonio, Texas.)] TJ ET BT 35.000 569.105 Td /F1 12.0 Tf [(??We are grateful that several abstracts highlighting our TTK and PLK4 inhibitor programs have been)] TJ ET BT 35.000 554.453 Td /F1 12.0 Tf [(selected for presentation,?)] TJ ET BT 183.080 554.453 Td /F1 12.0 Tf [()] TJ ET BT 186.416 554.453 Td /F1 12.0 Tf [( said Dr. Michael Tusche, Treadwell co-CEO. ??We look forward to)] TJ ET BT 35.000 539.801 Td /F1 12.0 Tf [(additional data from these studies, as we further characterize the utility of our agents in various breast)] TJ ET BT 35.000 525.149 Td /F1 12.0 Tf [(cancer settings.?)] TJ ET BT 132.380 525.149 Td /F1 12.0 Tf [()] TJ ET BT 35.000 498.497 Td /F1 12.0 Tf [(Information on the four abstracts:)] TJ ET BT 35.000 471.845 Td /F1 12.0 Tf [(Abstract Title: An Update to a Phase I Trial of CFI-402257, an oral TTK Inhibitor, in Patients with)] TJ ET BT 35.000 457.193 Td /F1 12.0 Tf [(Advanced Solid Tumors with HER2-Negative Breast Cancer Expansion Cohorts)] TJ ET BT 35.000 442.541 Td /F1 12.0 Tf [(Poster ID: P6-10-13)] TJ ET BT 35.000 427.889 Td /F1 12.0 Tf [(Session: Treatment: Therapeutic Strategies ?? Novel Targets and Targeted Agents)] TJ ET BT 35.000 413.237 Td /F1 12.0 Tf [(Date: Friday, December 9, 2022)] TJ ET BT 35.000 398.585 Td /F1 12.0 Tf [(Time: 7:00 am CT)] TJ ET BT 35.000 371.933 Td /F1 12.0 Tf [(Abstract Title: CCTG IND.236: A Phase 1b Trial of Combined CFI-402257 and Weekly Paclitaxel in)] TJ ET BT 35.000 357.281 Td /F1 12.0 Tf [(Patients with HER2 Negative \(HER2-\) Advanced Breast Cancer \(aBC\))] TJ ET BT 35.000 342.629 Td /F1 12.0 Tf [(Poster ID: P3-07-10)] TJ ET BT 35.000 327.977 Td /F1 12.0 Tf [(Session: Treatment: Therapeutic Strategies ?? New Drugs and Treatment Strategies)] TJ ET BT 35.000 313.325 Td /F1 12.0 Tf [(Date: Wednesday, December 7, 2022)] TJ ET BT 35.000 298.673 Td /F1 12.0 Tf [(Time: 5:00 pm CT)] TJ ET BT 35.000 272.021 Td /F1 12.0 Tf [(Abstract Title: CCTG IND.237: A phase II study of CFI-400945 in patients with advanced/metastatic)] TJ ET BT 35.000 257.369 Td /F1 12.0 Tf [(HER2-negative breast cancer)] TJ ET BT 35.000 242.717 Td /F1 12.0 Tf [(Poster ID: P3-07-14)] TJ ET BT 35.000 228.065 Td /F1 12.0 Tf [(Date: Wednesday, December 7, 2022)] TJ ET BT 35.000 213.413 Td /F1 12.0 Tf [(Time: 5:00 pm CT)] TJ ET BT 35.000 186.761 Td /F1 12.0 Tf [(Abstract Title: CCTG IND.239: A Phase 2 Study of Combined CFI-400945 and Durvalumab in Patients)] TJ ET BT 35.000 172.109 Td /F1 12.0 Tf [(with Advanced Triple Negative Breast Cancer \(aTNBC\))] TJ ET BT 35.000 157.457 Td /F1 12.0 Tf [(Poster ID: P3-07-18)] TJ ET BT 35.000 142.805 Td /F1 12.0 Tf [(Date: Wednesday, December 7, 2022)] TJ ET BT 35.000 128.153 Td /F1 12.0 Tf [(Time: 5:00 pm CT)] TJ ET BT 35.000 97.468 Td /F3 14.0 Tf [(About Treadwell Therapeutics)] TJ ET q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 1)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 8 0 obj << /Type /Font /Subtype /Type1 /Name /F1 /BaseFont /Helvetica /Encoding /WinAnsiEncoding >> endobj 9 0 obj << /Type /Font /Subtype /Type1 /Name /F2 /BaseFont /Times-Roman /Encoding /WinAnsiEncoding >> endobj 10 0 obj << /Type /Font /Subtype /Type1 /Name /F3 /BaseFont /Helvetica-Bold /Encoding /WinAnsiEncoding >> endobj 11 0 obj << /Type /ExtGState /BM /Normal /CA 1 >> endobj 12 0 obj << /Type /ExtGState /BM /Normal /ca 1 >> endobj 13 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Annots [ 15 0 R 17 0 R ] /Contents 14 0 R >> endobj 14 0 obj << /Length 1993 >> stream 0.000 0.000 0.000 rg BT 35.000 820.168 Td /F1 12.0 Tf [(Treadwell Therapeutics is a science driven, clinical-stage, multi-modality biotechnology company)] TJ ET BT 35.000 805.516 Td /F1 12.0 Tf [(developing first-in-class and best-in-class medicines to address unmet needs in patients with cancer.)] TJ ET BT 35.000 790.864 Td /F1 12.0 Tf [(The Company??s internally developed clinical pipeline includes CFI-400945, CFI-402257 \(TTK)] TJ ET BT 35.000 776.212 Td /F1 12.0 Tf [(inhibitor\) and CFI-402411 \(HPK1 inhibitor\). The company is also advancing a pre-clinical pipeline of)] TJ ET BT 35.000 761.560 Td /F1 12.0 Tf [(first-in-class antibody and TCR-based cell therapy assets. For more information, please visit)] TJ ET BT 35.000 746.908 Td /F1 12.0 Tf [(www.treadwelltx.com.)] TJ ET BT 35.000 716.224 Td /F3 14.0 Tf [(Contact)] TJ ET BT 35.000 687.034 Td /F1 12.0 Tf [(Investors:)] TJ ET 0.000 0.000 0.000 RG 0.6 w 0 J [ ] 0 d 35.000 684.424 m 87.020 684.424 l S 0.000 0.000 0.800 rg BT 35.000 672.382 Td /F1 12.0 Tf [(ir@treadwelltx.com)] TJ ET 0.000 0.000 0.800 RG 35.000 669.772 m 137.192 669.772 l S 0.000 0.000 0.000 rg BT 35.000 645.730 Td /F1 12.0 Tf [(General inquiries:)] TJ ET 0.000 0.000 0.000 RG 35.000 643.120 m 129.032 643.120 l S 0.000 0.000 0.800 rg BT 35.000 631.078 Td /F1 12.0 Tf [(info@treadwelltx.com)] TJ ET 0.000 0.000 0.800 RG 35.000 628.468 m 149.876 628.468 l S 0.000 0.000 0.000 rg BT 35.000 604.426 Td /F3 12.0 Tf [(Date Created)] TJ ET BT 35.000 589.774 Td /F1 12.0 Tf [(November 21, 2022)] TJ ET q 35.000 586.843 0.000 0.000 re W n Q /GS1 gs /GS2 gs q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 2)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 15 0 obj << /Type /Annot /Subtype /Link /F 28 /A 16 0 R /Border [0 0 0] /H /I /Rect [ 35.0000 670.0506 137.1920 682.2606 ] >> endobj 16 0 obj << /Type /Action /S /URI /URI (mailto:ir@treadwelltx.com) >> endobj 17 0 obj << /Type /Annot /Subtype /Link /F 28 /A 18 0 R /Border [0 0 0] /H /I /Rect [ 35.0000 628.7466 149.8760 640.9566 ] >> endobj 18 0 obj << /Type /Action /S /URI /URI (mailto:info@treadwelltx.com) >> endobj xref 0 19 0000000000 65535 f 0000000009 00000 n 0000000074 00000 n 0000000120 00000 n 0000000344 00000 n 0000000373 00000 n 0000000522 00000 n 0000000625 00000 n 0000005039 00000 n 0000005146 00000 n 0000005255 00000 n 0000005368 00000 n 0000005425 00000 n 0000005482 00000 n 0000005613 00000 n 0000007659 00000 n 0000007792 00000 n 0000007869 00000 n 0000008002 00000 n trailer << /Size 19 /Root 1 0 R /Info 5 0 R /ID[] >> startxref 8081 %%EOF